Hansa Biopharma is leveraging its proprietary enzyme technology platform to develop immunomodulatory treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer.
The Company’s lead product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and tissue transplantation and acute autoimmune indications. Imlifidase is currently under review for a potential marketing authorization by European Medicines Agency (EMA).
On the forefront of healthcare change, Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients worldwide.
Astellas Pharma is a global pharmaceutical company with a simple vision – to produce exceptional medicines that change tomorrow for patients in need. We strive to develop therapies that are first-in-class and best-in-class. Treatments that offer patients and their doctors genuinely new options for improving care.
Sandoz, a Novartis division, is a world leader in generic pharmaceuticals and biosimilars, finding innovative ways to make high-quality medicines affordable, without compromising on patient management.
For over 30 years, the combined Novartis organisation has been committed to the field of transplantation, bringing new treatments to market to individualise therapy and optimize patient outcomes.